Ankit Mahadevia
CEO and President at Spero Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Spero Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Spero Therapeutics Inc. October 5, 202399.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 28, 2025 | Spero Therapeutics Inc. | Open-market sale | −6,572 | $1.97 | $12,947 |
| Jun 12, 2025 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −13,959 | $0.78 | $10,888 |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −55,260 | $0.78 | $43,103 |
| Aug 27, 2024 | Spero Therapeutics Inc. | Open-market sale | −5,912 | $1.35 | $7,981 |
| May 29, 2024 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Feb 2, 2024 | Spero Therapeutics Inc. | Open-market sale | −63,795 | $1.37 | $87,399 |
| Oct 5, 2023 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Aug 28, 2023 | Spero Therapeutics Inc. | Open-market sale | −9,040 | $1.26 | $11,390 |
| Feb 3, 2023 | Spero Therapeutics Inc. | Open-market sale | −12,286 | $1.81 | $22,238 |
| Feb 1, 2023 | Spero Therapeutics Inc. | Grant or award | +531,914 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.